Article
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
Trials - 7 Mar 2017
Cranston Amy, Stocken Deborah D, Stamp Elaine, Roblin David, Hamlin Julia, Langtry James, Plummer Ruth, Ashworth Alan, Burn John, Rajan Neil
Abstract excerpt
BACKGROUND: Patients with germline mutations in a tumour suppressor gene called CYLD develop multiple, disfiguring, hair follicle tumours on the head and neck. The prognosis is poor, with up to one in four mutation carriers requiring complete surgical removal of the scalp. There are no effective medical alternatives to treat this condition. Whole genome molecular profiling experiments led to the discovery of an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.